ARALDI, GIAN LUCA:1238759 [14-013441] IGF:CL:IGF IGF::CL::IGF
阿拉尔迪,吉安·卢卡:1238759 [14-013441] IGF:CL:IGF IGF::CL::IGF
基本信息
- 批准号:8950716
- 负责人:
- 金额:$ 7.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-28 至 2015-09-27
- 项目状态:已结题
- 来源:
- 关键词:AddressBiological AssayBiologyContractsDevelopmentDevelopment PlansDiseaseFundingFutureIndustryInstitutesLeadLeadershipModelingNeurosciencesNeurosciences ResearchPeer ReviewPharmaceutical PreparationsPrincipal InvestigatorProcessResearchResearch ContractsResearch PersonnelSeasonsShapesTherapeuticUnited States National Institutes of HealthWorkdesigndrug developmentexperienceinnovationmeetingsnervous system disorderprogramsvirtual
项目摘要
the NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development; a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma
Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT).
代表16个NIH研究所和中心的NIH神经科学研究蓝图宣布了神经治疗学的巨大挑战,以解决神经系统疾病有效药物的缺乏。为了迎接这一重大挑战,NIH蓝图正在开创一种新的药物开发模式;一个将行业药物开发专业知识与创新疾病生物学相结合的网络,这是NIH资助研究的优势。蓝图神经治疗网络将作为一个虚拟的制药公司运作,
具有令人信服的治疗原理和药物开发项目起始材料的神经科学研究人员(主要研究者)将与设计和指导药物开发计划的高级,行业经验丰富的顾问相匹配。主要研究者将进行生物活性测定和生物学工作,由NIH通过单独合同确定和资助的合同研究组织(CRO)将实施所有其他药物开发活动。参与项目的主要研究者、顾问、NIH工作人员和CRO工作人员将组成牵头开发团队(LDT)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GIAN ARALDI其他文献
GIAN ARALDI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GIAN ARALDI', 18)}}的其他基金
PROCESS CHEMISTRY CONSULTING SERVICES. KEY PERSONNEL CONSULTANT: DR. GIAN ARALDI.
工艺化学咨询服务。
- 批准号:
10721072 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
PHARMACEUTICS FORMULATION/CHEMISTRY MANUFACTURING AND CONTROL CONSULTING SERVICES FOR SMALL MOLECULES AND/OR BIOLOGICS
小分子和/或生物制剂的药物制剂/化学制造和控制咨询服务
- 批准号:
10721143 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
PHARMACEUTICS FORMULATION/CHEMISTRY MANUFACTURING AND CONTROL CONSULTING SERVICES FOR SMALL MOLECULES AND/OR BIOLOGICS
小分子和/或生物制剂的药物制剂/化学制造和控制咨询服务
- 批准号:
10788021 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
PROCESS CHEMISTRY CONSULTING SERVICES. KEY PERSONNEL CONSULTANT: DR. GIAN ARALDI.
工艺化学咨询服务。
- 批准号:
10827835 - 财政年份:2022
- 资助金额:
$ 7.5万 - 项目类别:
PHARMACEUTICS/FORMULATION/CMC CONSULTING SERVICES FOR NINDS HEAL PROGRAM
NINDS HEAL 计划的药剂/制剂/CMC 咨询服务
- 批准号:
10497999 - 财政年份:2021
- 资助金额:
$ 7.5万 - 项目类别:
ARALDI, GIAN LUCA:1238759 [14-013441] IGF:CL:IGF IGF::CL::IGF
阿拉尔迪,吉安·卢卡:1238759 [14-013441] IGF:CL:IGF IGF::CL::IGF
- 批准号:
9089787 - 财政年份:2014
- 资助金额:
$ 7.5万 - 项目类别:
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 7.5万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 7.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 7.5万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 7.5万 - 项目类别:
Postdoctoral Fellowships